Pepdox
Studies
Peptides
Calculator
In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk. | Pepdox
Home
/
Search
/
PMID 38048584
In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
Annals of internal medicine
2023
PMID: 38048584
View on PubMed
DOI: 10.7326/J23-0101
Semaglutide
Abstract
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators.N Engl J Med. 2023;389:1069-1084. 37622681.
Authors
Ali, Hyeon-Ju; Deswal, Anita